RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference
23 August 2023 - 10:05PM
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a
specialty pharmaceutical company, today announced that Brian
Markison, Chief Executive Officer, will participate in a fireside
chat and host 1x1 investor meetings at the H.C. Wainwright 25th
Annual Global Investment Conference in New York City as follows:
Date: |
Tuesday, September 12, 2023 |
|
|
Time: |
11:30 am ET |
|
|
Webcast: |
Click here |
To schedule a 1x1 investor meeting with the
Company, please contact meetings@hcwco.com at H.C. Wainwright.
The live and archived webcast of the fireside
chat will be accessible from the Company’s website at
www.rvlpharma.com, under the Investors & News section. The
archived replay of the webcast will be accessible for 90 days.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty
pharmaceutical company focused on the commercialization of UPNEEQ®
(oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the
treatment of acquired blepharoptosis, or low-lying eyelid, in
adults. UPNEEQ is the first non-surgical treatment option approved
by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals
plc
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
IMPORTANT SAFETY INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic
solution), 0.1% is indicated for the treatment of acquired
blepharoptosis in adults.
WARNINGS AND PRECAUTIONS
- Ptosis may be
associated with neurologic or orbital diseases such as stroke
and/or cerebral aneurysm, Horner syndrome, myasthenia gravis,
external ophthalmoplegia, orbital infection and orbital masses.
Consideration should be given to these conditions in the presence
of ptosis with decreased levator muscle function and/or other
neurologic signs.
-
Alpha-adrenergic agonists as a class may impact blood pressure.
Advise UPNEEQ patients with cardiovascular disease, orthostatic
hypotension, and/or uncontrolled hypertension or hypotension to
seek medical care if their condition worsens.
- Use UPNEEQ with
caution in patients with cerebral or coronary insufficiency or
Sjögren’s syndrome. Advise patients to seek medical care if signs
and symptoms of potentiation of vascular insufficiency
develop.
- UPNEEQ
may increase the risk of angle closure glaucoma in patients with
untreated narrow-angle glaucoma. Advise patients to seek immediate
medical care if signs and symptoms of acute narrow-angle glaucoma
develop.
-
Patients should not touch the tip of the single patient-use
container to their eye or to any surface, in order to avoid eye
injury or contamination of the solution.
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of
subjects treated with UPNEEQ were punctate keratitis, conjunctival
hyperemia, dry eye, blurred vision, instillation site pain, eye
irritation and headache.
DRUG INTERACTIONS
-
Alpha-adrenergic agonists, as a class, may impact blood pressure.
Caution in using drugs such as betablockers, anti-hypertensives,
and/or cardiac glycosides is advised. Caution should also be
exercised in patients receiving alpha adrenergic receptor
antagonists such as in the treatment of cardiovascular disease, or
benign prostatic hypertrophy.
- Caution is
advised in patients taking monoamine oxidase inhibitors which can
affect the metabolism and uptake of circulating amines.
RVL Pharmaceuticals (NASDAQ:RVLP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
RVL Pharmaceuticals (NASDAQ:RVLP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024